daratumumab + pomalidomide + dexamethasone

The combination of daratumumab + pomalidomide + dexamethasone (often abbreviated as DPd) is a therapeutic regimen used for treating multiple myeloma, particularly in patients who have received prior therapies. This combination leverages the complementary mechanisms of action of each component to target multiple myeloma cells effectively. ## Description Daratumumab + pomalidomide + dexamethasone (DPd) is a combination therapy for relapsed or refractory multiple myeloma. Daratumumab is a monoclonal antibody targeting CD38, which is highly expressed on myeloma cells. It works through multiple mechanisms including direct killing of myeloma cells, recruitment of immune cells (macrophages and natural killer cells), and modulation of the immune response[6]. Pomalidomide is an immunomodulatory drug that enhances daratumumab's efficacy by upregulating CD38 expression on myeloma cells and synergistically enhancing antibody-dependent cell-mediated cytotoxicity[4]. Dexamethasone is a corticosteroid that helps reduce inflammation and suppress immune responses that might contribute to myeloma progression. This combination has shown significant efficacy in patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor[7][8]. ## Administration The regimen is typically administered in 28-day cycles: - Pomalidomide: 4 mg orally daily from days 1 to 21 - Daratumumab: 16 mg/kg intravenously on days 1, 8, 15, and 22 (cycles 1-2), days 1 and 15 (cycles 3-6), and day 1 (cycle ≥7) - Dexamethasone: 40 mg (age ≤75 years) or 20 mg (age >75 years) orally on days 1, 8, 15, and 22[8] ## Efficacy In clinical studies, DPd has demonstrated significant efficacy in treating relapsed/refractory multiple myeloma. The MM-014 trial showed a median overall survival of 56.7 months with this combination[8]. Another study reported an overall response rate of 59%, with complete responses in 5.8% of patients and stringent complete responses in 7.8%[2]. The median duration of response was 13.6 months[2]. ## Side Effects Common side effects of the DPd combination include: - Infusion-related reactions (50%) - Hematological toxicities: neutropenia (82%), lymphopenia (71%), anemia, and thrombocytopenia - Fatigue (50%) - Upper respiratory tract infection (50%) - Diarrhea (38%) - Other common effects: cough, nausea, back pain, fever, constipation, shortness of breath, muscle spasms, insomnia, joint pain, vomiting, dizziness, and chills[6][7] The safety profile is generally consistent with the known profiles of the individual components, with the exception of daratumumab-specific infusion-related reactions and a higher incidence of neutropenia, although without an increase in infection rates[4]. This combination represents an important treatment option for patients with multiple myeloma who have received at least two prior therapies, particularly those who have exhausted the benefits of lenalidomide treatment.

Other names

DPd